Translational Research

Translational Research

Translational research transforms scientific discoveries arising from fundamental studies into clinical applications to improve outcomes for patients with prostate cancer. Members of this team work together to employ innovative new technologies for biomarker discovery, detection and quantification that have been developed independently in internationally-recognized efforts in Alberta and bring them to bear on a common goal – developing better tests for prostate cancer.

The combination of prognostic biomarkers from distinct aspects of prostate cancer progression resulted in a test that is more sensitive, more accurate and more cost effective than current tests for prostate cancer.

Our overall goal is to improve patient outcomes and quality of life by translating novel tests to the clinic that are more sensitive, more accurate and more cost-effective than current tests for prostate cancer. No one dies from prostate cancer that is localized to the prostate – the spread, or metastasis, of prostate cancer is what makes it so dangerous. The five year survival rate for localized prostate cancer in North America is close to 100%, yet this drops to 30% for metastatic disease. The metastasis of prostate cancer is driven primarily by changes in growth factors, extracellular proteases, and the cell migration machinery. Biomarkers that are involved in these processes are prognostic for metastatic prostate cancer and their integration into a single powerful test are the focus of this multi-disciplinary team.

Our team is integrating internationally-recognized efforts in the characterization of tumour cell migration, growth factor signaling and protease-activated receptors to develop novel multiplex tests to more accurately predict outcomes in prostate cancer.

translational-research-image

APCaRI at the Enbridge Ride to Conquer Cancer for second year

Well, we did it again!  Several APCaRI members participated in a 2-day major cycling event called the Enbridge Ride to Conquer Cancer, benefiting the Alberta Cancer Foundation. We cycled 228 kms over 2 days along the majestic Rockies with thousands of other Riders, supported by an amazing team of volunteers. Riding along with over 50 members of the Cross Cancer Institute Team, and 1402 riders in total, it was an epic experience!
Most importantly, we raised $6.35M to support cutting edge cancer research in Alberta. We are very thankful for the support we received, which will help us to beat prostate cancer.

If you didn’t get a chance to support one of our riders, please consider contributing to the team’s efforts at our DONATE page.

- Catalina Vasquez

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.